Don't close this page .. Test is protected .. Answers cannot be changed .. We try now to connect to save and correct your answers.
Connection trial number:
If this message persists for long, please check your internet connection.
This test is monitored
Switching to another webpage or any other program is considered a cheating behavior and your test may be automatically terminated.
Okay
Important Notice
If you moved to the next question, you will not be able to come back to this question again.
Cancel
Move to next question
Final exam لمادة موضوعات مختارة في علم الادوية
Student data
×
Student data
Student name: ***
Student number: ***
Class or section: ***
Test instructions
×
Test instructions
عدد الاسءلة هي 63 سؤال
Page direction
×
Change page direction
Right to left
Left to right
Q1
Score: 0.5
A- albumin
B- alpha-1 acid glycoproteins
C- T cell
Q2
Score: 0.5
A- chemical development
B- safety assessment
C- drug metabolism
D- all the above
Q3
Score: 0.5
صح
خطأ
Q4
Score: 0.5
Q5
Score: 0.5
A- mental retardation
B- Hyperactivity
C- all the above
D- non of the above
Q6
Score: 0.5
Q7
Score: 0.5
A- drugs
B- food additives
C- cosmetic
D- pesticide
E- all of the above
Q8
Score: 0.5
A- In vivo
B- in human
C- in animal
D- in vitro
Q9
Score: 0.5
صح
خطأ
Q10
Score: 0.5
A- Clark's Rule
B- Youngs Rule
C- creatinine clearance
D- non the above
Q11
Score: 0.5
A- absorption
B- medication compliance
C- reduction in GI motility
D- Elimination
E- A+ D
F- all the above
Q12
Score: 0.5
A- Elderly people
B- Infant
C- they are the major consumer of drug
D- include polypharmacy
Q13
Score: 0.5
صح
خطأ
Q14
Score: 0.5
A- chemical modification of known molecule
B- biotechnology and cloning
C- random screening for biological activity of large numbers of natural
D- all the above
Q15
Score: 0.5
Q16
Score: 0.5
صح
خطأ
Q17
Score: 0.5
A- result in polar
B- water soluble
C- oxidase
D- conjugation
Q18
Score: 0.5
صح
خطأ
Q19
Score: 0.5
A- sulfonamide
B- Aspirin
C- Mepiridine
D- Benzodiazepine
Q20
Score: 0.5
A- nasal hypoplasia
B- bone stippling on X- Ray
C- depressed bridge of nose
D- all the above
E- non the above
Q21
Score: 0.5
A- factor including the vascular perfusion
B- By 6 weeks of age
C- such as penicillin
D- are reduced by 50% in premature
Q22
Score: 0.5
A- mental retardation
B- Mutagenesis
C- is seen in up to 25% of the fetuses with first - trimester exposure to coumarins
D- carcinogenesis
Q23
Score: 0.5
A- 5- 10 years
B- 1 month
C- 15- 25 years
D- 9 month to 3 years
Q24
Score: 0.5
A- usually placebo controlled
B- phase IIa is exploratory and phase IIb is confirmatory
C- the opproxinate number of healthy subject is 50- 500
D- gives confirmation of clinical dose and regimen for efficacy
Q25
Score: 0.5
صح
خطأ
Q26
Score: 0.5
صح
خطأ
Q27
Score: 0.5
Q28
Score: 0.5
صح
خطأ
Q29
Score: 0.5
A- producing hypotension
B- producing hypoglycemia
C- producing hypertension
D- producing hyperglycemia
Q30
Score: 0.5
A- structural
B- spontaneous
C- antidotal
D- route of exposure
Q31
Score: 0.5
صح
خطأ
Q32
Score: 0.5
A- fetal period
B- organogenesis
C- Blastogenesis
D- non the above
Q33
Score: 0.5
A- spontaneous
B- route of exposure
C- species
D- sex of test animal formulation
Q34
Score: 0.5
A- digoxin
B- NSAIDS
C- Atropine- like drugs
Q35
Score: 0.5
صح
خطأ
Q36
Score: 0.5
A- Arthritis
B-metabolism
C- peptic ulcer
D- stroke
Q37
Score: 0.5
A- digoxin
B- TCAS
C- Atropine like drugs
Q38
Score: 0.5
Q39
Score: 0.5
A- pharmacodynamic
B- direct toxicity
C- genotoxicity
D- all the above
Q40
Score: 0.5
صح
خطأ
Q41
Score: 0.5
Q42
Score: 0.5
A- Antibodies
B- vaccines
C- enzyme
D- DNA product
Q43
Score: 0.5
A- Health
B- disease
C- organization
D- non the above
Q44
Score: 0.5
A- lethal dose to assayed in the same population
B- dose required for sub- lethal toxicity
C- all the above
Q45
Score: 0.5
Q46
Score: 0.5
صح
خطأ
Q47
Score: 0.5
صح
خطأ
Q48
Score: 0.5
A- dose
B- Age
C- systemic toxicity
D- Route
Q49
Score: 0.5
A- Easily
B- with difficult
C- poorly
D- non of the above
Q50
Score: 0.5
صح
خطأ
Q51
Score: 0.5
A- treatment of pre- existing chronic disorder
B- always use drugs which have been widely used
C- over the counter
D- drugs for medical condition prior to confirmation of pregnancy
Q52
Score: 0.5
A- urinary retention
B- hyperglycemia
C- heart block
D- GI hemorrhage
Q53
Score: 0.5
Q54
Score: 0.5
A- FDA
B- NMR
C- IND
Q55
Score: 0.5
A- conducting a clinical trial
B- Analyzing the outcome of a clinical trial
C- Givrine permission so clinical trial
D- non the above
Q56
Score: 0.5
Q57
Score: 0.5
A- category A
B- category B
C- category c
D- category D
E- category x
Q58
Score: 0.5
A- gene
B- protein
C- cell
D- tissue
Q59
Score: 0.5
A- drug action
B- cell
B- tissue
C- system
Q60
Score: 0.5
A- pharmacodynamic drug- drug interaction
B- pharmacokinetic drug- drug interaction
C- pharmaceutic interaction
Q61
Score: 0.5
Q62
Score: 0.5
صح
خطأ
Q63
Score: 0.5
A- transplant surgery
B- Apligraf
C- B cell
D- influenza
Q64
Score: 0.5
صح
خطأ
Q65
Score: 0.5
A- Aspirin
B- sulfonamide
C- chloramphenicol
D- Tetracycline
Q66
Score: 0.5
A- phase I
B- phase II
C- phaseI and II and III and IV
D- phase III
Q67
Score: 0.5
A- poly pharmacy
B- multiple disease state
C- increase severity of illness
D- B+ C
E- all the above
Q68
Score: 0.5
صح
خطأ
Q69
Score: 0.5
A- animal
B- human
C- in vivo
Q70
Score: 0.5
Q71
Score: 0.5
A- pregnancy
B- cough
C- diarrhea
D- heart
Q72
Score: 0.5
A- phase -1
B- phase- 2
Q73
Score: 0.5
A- check chemical stability
B- determine major metabolite
C- optimize and scale up synthesis and purification
D- produce GMP batches are required for biological and clinical test
Q74
Score: 0.5
A- Effect
B- Efficacy
C- Effectiveness
D- BENEFIT
Q75
Score: 0.5
A- pharmaceutic interaction
B- pharmacodynamic interaction
C- pharmacokinetic interaction
Q76
Score: 0.5
صح
خطأ
Q77
Score: 0.5
صح
خطأ
Q78
Score: 0.5
A- strength of hypothesis
B- Availibility of target
C- market prediction
D- Toxicology
Q79
Score: 0.5
A- vaccination
B- blood transfusion
C- transplantation
D- drug therapy
Q80
Score: 0.5
صح
خطأ
Questions you haven't answered yet:
Are you sure you want to end this test and send your answers?
All copy rights reserved
©
arab-exams.com
2014-2023
Dismiss this alert